


# SETTING THE SCENE:



## ADAMU ADDISSIE

Co CEO Network for Oncology Research in  
Sub-Saharan Africa



Co-funded by  
the European Union



EUROPEAN ALLIANCE  
FOR PERSONALIZED MEDICINE



# VISION EUROPE 2030

## DISRUPTIVE TECHNOLOGIES, DEMOCRATIZED TRIALS & NEXT-GEN TREATMENT PARADIGMS



September 2-3, 2025 | Club University Foundation





# Innovation Without Access Is Failure: Delivering Genomic Equity in High-Tech Health Systems


**Adamu Addissie MD MPH PhD**  
**Director**  
**Network for Oncologic Research in Africa (NORA)**  
**Addis Ababa University, Ethiopia**  
**[adamu.addissie@aau.edu.et](mailto:adamu.addissie@aau.edu.et)**



Co-funded by  
the European Union



EUROPEAN ALLIANCE  
FOR PERSONALIZED MEDICINE



# Background


- Genomics holds immense potential for improving health in low-resource environments (e.g., early disease detection, tailored treatments including cancer care).
- Without equitable access, low-income populations risk being further excluded from scientific and medical advancements. Genomic innovation that doesn't reach all populations can reinforce historical and structural inequities in global health.



Co-funded by  
the European Union



EUROPEAN ALLIANCE  
FOR PERSONALIZED MEDICINE



# Key Issues to be Tackled


- LMICs are often in the receiving ends of innovations while being major contributors in global research rather as a study population.
- This is the case in many innovative research including genetic and genomic studies.
- This is further compounded by socio-economic and political vulnerabilities owing to
  - low-levels of science literacy,
  - lack of access to information technology etc.
- Current Global treaties and international regulations should be enhanced to ensure equitable access benefits of such innovative research be fairly negotiated at all cycles of such innovative research.



Co-funded by  
the European Union



EUROPEAN ALLIANCE  
FOR PERSONALIZED MEDICINE



# SWOT ANALYSIS

## Strengths:

**Contextual potential**

## Opportunities:

**New equitable collaborative frameworks**

## Weaknesses:

**Lack of systems approach**

## Threats:

**Neo-colonial approaches and perspectives**



Co-funded by  
the European Union



EUROPEAN ALLIANCE  
FOR PERSONALIZED MEDICINE



# Policy Recommendations


- One important policy consideration mainstreaming context-tailored scientific citizenship and public engagement with science (PES).




Co-funded by  
the European Union



EUROPEAN ALLIANCE  
FOR PERSONALIZED MEDICINE





# A CALL TO ACTION

*Join the movement!*



Co-funded by  
the European Union